Increasing Awareness and Identification of Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Program.
5 affiliations
- 1From the Division of Endocrinology, Boston Children's Hospital, Boston, Mass.
- 2Department of Pediatrics, Harvard Medical School, Boston, Mass.
- 3The Broad Institute of MIT and Harvard, Cambridge, Mass.
- 4Division of Endocrinology & Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pa.
- 5University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
Abstract
Maturity-onset diabetes of the young (MODY) is frequently misdiagnosed, but an accurate diagnosis can inform tailored diabetes management. A quality improvement project was launched in 2022 at a pediatric tertiary care center to (1) increase MODY testing among individuals with islet autoantibody-negative (IAb-) new-onset diabetes mellitus (NODM) and (2) increase provider awareness of MODY. Interventions targeted the primary drivers, including provider recognition of MODY and barriers to testing. Each month, an electronic medical record report identified patients with IAb- NODM diagnosed within the prior 3 months. A standardized previsit email was sent to the treating provider that (1) flagged IAb- status, (2) outlined MODY testing criteria, and (3) provided instructions for ordering genetic testing when indicated. The primary outcome, MODY tests ordered among eligible patients, was analyzed longitudinally using a control chart. Provider awareness of MODY and perceptions of the intervention were assessed in May 2023 and March 2024. The proportion of patients with IAb- NODM tested for MODY at a clinic visit within 365 days of diagnosis increased from 2.87% at baseline (January/February 2021-May/June 2022) to 9.94% after the quality improvement project launch in July/August 2022. Among completed tests through October 2025, 9 of 28 (32.1%) identified a pathogenic or likely pathogenic MODY variant. Providers' familiarity with MODY testing criteria also improved, with those reporting being "extremely familiar" increasing from 0% (0/20) to 17% (3/18). The project, including the targeted previsit provider email, was associated with increased MODY testing and improved provider awareness in a pediatric diabetes clinic.
Related
- Identification of CLOCK and MARK2 as Candidate Blood-Based Biomarkers in Type 2 Diabetes: An Integrated Bulk and Single-Cell Transcriptomic Study
- Agentic LLM reasoning in pediatric diabetes outcome prediction from multimodal medical records
- Transcriptional coactivator MED15 is required to maintain β-cell maturity
- EEG emotion-recognition datasets for neuroarchitecture: an appraisal of openness, AI-readiness and ontology maturity
- Macrophages in non-infectious uveitis: cell origin, disease stage, evidence provenance, and therapeutic maturity
BibTeX
@article{kreienkamp2026increasing,
title = {{Increasing Awareness and Identification of Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Program.}},
author = {Raymond J Kreienkamp and Jessica L Ruiz and Sarah Schlegel and Olivia Sterns and Jia Zhu and Tara Maxwell and Christine E Cherella and Erinn T Rhodes},
journal = {Pediatric quality \& safety},
year = {2026},
month = oct,
doi = {10.1097/pq9.0000000000000937},
url = {https://europepmc.org/article/MED/42953899},
note = {CC BY},
}
RIS
TY - JOUR
TI - Increasing Awareness and Identification of Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Program.
AU - Raymond J Kreienkamp
AU - Jessica L Ruiz
AU - Sarah Schlegel
AU - Olivia Sterns
AU - Jia Zhu
AU - Tara Maxwell
AU - Christine E Cherella
AU - Erinn T Rhodes
PY - 2026
DA - 2026/10/28
JO - Pediatric quality & safety
DO - 10.1097/pq9.0000000000000937
UR - https://europepmc.org/article/MED/42953899
AB - Maturity-onset diabetes of the young (MODY) is frequently misdiagnosed, but an accurate diagnosis can inform tailored diabetes management. A quality improvement project was launched in 2022 at a pediatric tertiary care center to (1) increase MODY testing among individuals with islet autoantibody-negative (IAb-) new-onset diabetes mellitus (NODM) and (2) increase provider awareness of MODY. Interventions targeted the primary drivers, including provider recognition of MODY and barriers to testing. Each month, an electronic medical record report identified patients with IAb- NODM diagnosed within the prior 3 months. A standardized previsit email was sent to the treating provider that (1) flagged IAb- status, (2) outlined MODY testing criteria, and (3) provided instructions for ordering genetic testing when indicated. The primary outcome, MODY tests ordered among eligible patients, was analyzed longitudinally using a control chart. Provider awareness of MODY and perceptions of the intervention were assessed in May 2023 and March 2024. The proportion of patients with IAb- NODM tested for MODY at a clinic visit within 365 days of diagnosis increased from 2.87% at baseline (January/February 2021-May/June 2022) to 9.94% after the quality improvement project launch in July/August 2022. Among completed tests through October 2025, 9 of 28 (32.1%) identified a pathogenic or likely pathogenic MODY variant. Providers' familiarity with MODY testing criteria also improved, with those reporting being "extremely familiar" increasing from 0% (0/20) to 17% (3/18). The project, including the targeted previsit provider email, was associated with increased MODY testing and improved provider awareness in a pediatric diabetes clinic.
SN - 2472-0054
ER -